The co-founders of vaccine maker BioNTech are stepping down to launch a venture focused on next-generation messenger RNA ...

The company’s co-founders said they are leaving to start a new mRNA-based company.

Uğur Şahin and Özlem Türeci, a Turkish husband-and-wife team, became unlikely celebrities during the pandemic for their world ...

The leadership changes arrive as BioNTech reported a 57% rise in net losses for 2025.

By Ludwig Burger FRANKFURT, March 10 (Reuters) - The two co-founders and leading executives of Germany's BioNTech will leave the COVID-19 vaccine maker by the end of 2026 to start again with a new ...

The stock was down 14% premarket after BioNTech announced the departures and issued revenue guidance that fell short of Wall ...

BioNTech SE’s founders will leave the company to start a new biotech focused on messenger RNA, the technology behind their blockbuster Covid-19 vaccine, dashing investors’ confidence in the firm’s ...

If you are wondering whether BioNTech is starting to look like value after the Covid vaccine boom faded, or if the current price still feels rich, this article walks through what the numbers actually ...

BioNTech (BNTX) stock slides as 2026 revenue outlook misses forecasts and a CEO succession begins. Read more here ...

Q4 2025 earnings call: 2026 revenue guidance, COVID vaccine outlook, oncology pipeline updates, and leadership transition—read now.

Nothing about the recent past, present, or foreseeable future seems all that compelling.

The world could be only a few years away from a cancer vaccine, according to the couple behind the Pfizer/BioNtech COVID-19 vaccine. "We feel that a cure for cancer or to changing cancer patients' ...